Recent News Releases
For investor-related news, see our ASX releases here.
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Apr 9, 2019Leading global biotech company brings innovative therapies for life-threatening medical conditions to UAE
Dubai, UAE - 9 April, 2019 – CSL Behring, a global biotherapeutics leader, has inaugurated its regional headquarters at Dubai Science Park (DSP), a holistic science-focused business community...
-
Mar 26, 2019CSL Behring announced today that Japan’s Ministry of Health, Labour and Welfare has approved two of its immunoglobulin therapies for the treatment of patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): Hizentra® and Privigen®
26 Mar 2019 Hizentra® [human normal immunoglobulin, 20%, subcutaneous] is the first and only subcutaneous immunoglobulin approved for the maintenance treatment of CIDP in Japan, based on findings...
-
Mar 15, 2019
MELBOURNE, Australia - CSL today announced its continued partnership with the National Youth Science Forum (NYSF) signing a new three-year agreement in support of programs that encourage life-long...
-
Mar 14, 2019
VIFOR PHARMA GROUP REPORTS STRONG 2018 RESULTS, EXCEEDING RAISED GUIDANCE THE VIFOR PHARMA GROUP REPORTED A STRONG SALES AND PROFIT PERFORMANCE IN 2018 WITH CONTINUED SOLID GROWTH FROM ITS THREE...
-
Feb 4, 2019Reinforces Commitment to Providing Global Bleeding Disorders Community with Access to Care and Efforts to Increase Awareness
04 Feb 2019 MONTREAL and KING OF PRUSSIA, Pa. – 4 February 2019 – The World Federation of Hemophilia (WFH) and global biotherapeutics leader CSL Behring today announced that the company has...
-
Jan 24, 2019
Companies plan to file for full marketing approval to EMA and FDA in 2020 MOUNTAIN VIEW, Calif. and ZURICH, 24 January, 2019 – ChemoCentryx, Inc. and Vifor Fresenius Medical Care Renal Pharma...
-
Jan 22, 2019
Re-analysis of the PIVOTAL data by the investigators has revealed that proactive, high-dose Venofer® compared to reactive, low-dose Venofer® resulted in: Superiority and statistically...
-
Jan 16, 2019Forbes Recognizes the Global Biotechnology Leader in its Top 50 Best Employers for Diversity 2019
16 Jan 2019 KING OF PRUSSIA, Pa. – January 16, 2019 – Forbes magazine has named global biotechnology leader CSL Limited as one of The Best Employers for Diversity in the United States. CSL,...
-
Jan 14, 2019
This news release is intended for Health Professional media only. Seqirus to launch its cell-based influenza vaccine in Europe for the 2019-20 season Real-world data indicates cell-based influenza...
-
Jan 7, 2019CSL announced that it will present at the 2019 J.P. Morgan Annual Healthcare Conference.
07 Jan 2019 King of Prussia, Pa – Global biotechnology giant CSL Limited, parent company of biotherapeutics leader CSL Behring and world-leading influenza provider Seqirus, today announced that...
-
Dec 14, 2018
The Honourable John Brumby AO today formally opened the new ‘Nancy Millis’ building, an expansion of the Bio21 Institute of Molecular Science and Biotechnology, University of Melbourne,...
-
Dec 12, 2018
Vifor Pharma Group is pleased to announce the appointment of Patrick Treanor as President of Relypsa on a permanent basis. He is also appointed to the Executive Committee of Vifor Pharma Group...
-
Dec 6, 2018Perreault leads the fifth largest biotechnology company in the world with more than 22,000 employees providing lifesaving medicines to patients in more than 60 countries.
06 Dec 2018 KING OF PRUSSIA, Pa. – December 6, 2018 – Paul Perreault, CEO and Managing Director of CSL Limited, is one of the Philadelphia Business Journal’s Most Admired CEOs for 2018,...
-
Dec 5, 2018
CSL spotlights developments in cell-based vaccine technology at Australian Research and Development briefing CSL Limited (ASX:CSL; USOTC:CSLLY) subsidiary Seqirus, today presented new real-world...
-
Nov 26, 2018
This year’s Iron Deficiency Day (26 November 2018) aims to raise awareness of the serious public health problems posed by iron deficiency and iron deficiency anaemia and highlight the negative...
-
Nov 16, 2018
This news release is intended for Health Professional media only. 16 Nov 2018 Seqirus, a global leader in influenza prevention, today released a new real-world evidence analysis indicating that...
-
Nov 16, 2018
The expansion will allow Seqirus to increase capacity for formulation, fill and finish manufacturing of cell-based and adjuvanted influenza vaccines for global markets. 16 Nov 2018 Seqirus, a...
-
Nov 8, 2018Results highlight need for new pathways and therapeutic strategies to manage costs and maintain quality of care for multi-vessel disease patients
08 Nov 2018 King of Prussia, Pa. – 08 November 2018 – Global biotherapeutics leader CSL Behring in collaboration with Health Analytics, a prominent health economics and outcomes research...
-
Nov 8, 2018Results highlight need for new pathways and therapeutic strategies to manage costs and maintain quality of care for multi-vessel disease patients
08 Nov 2018 King of Prussia, Pa. – 08 November 2018 – Global biotherapeutics leader CSL Behring in collaboration with Health Analytics, a prominent health economics and outcomes research...
-
Oct 29, 2018
PIVOTAL TRIAL CONFIRMS LONG-TERM SAFETY AND EFFICACY OF IV IRON DOSING STRATEGY PIVOTAL TRIAL CONFIRMS LONG-TERM SAFETY AND EFFICACY OF INTRAVENOUS IRON DOSING STRATEGY ALLOWING HIGHER FERRITIN...
-
Oct 22, 2018Partnership to identify and help commercialize potential new medicines at research and academic institutions across the Greater Philadelphia region
22 Oct 2018 PHILADELPHIA, Pa. – October 22, 2018 – The University City Science Center and global biotechnology leader CSL Behring, which has its operational headquarters in King of Prussia,...
-
Oct 22, 2018ESID platinum sponsor to partner with experts examining causes of secondary immunodeficiency
22 Oct 2018 LISBON, Portugal – 22 October 2018 – Global biotherapeutics leader CSL Behring today announced that it will host a panel of cross-specialty experts at its “Current and Emerging...
-
Oct 19, 2018
Subject to final approval by the European Commission, Seqirus plans to launch the vaccine as FLUCELVAX® TETRA1 in Europe for the 2019/20 influenza season. 19 Oct 2018 Seqirus, a global leader in...
-
Oct 11, 2018
Two Australian scientists have each been awarded an AUD$1.25 million, five-year, CSL Centenary Fellowship to further research into why so many people die from infection following stroke and how we...
-
Oct 9, 2018CSL, the parent company of CSL Behring, today announced an AUD$50,000 donation in support of Indonesian earthquake and tsunami relief efforts.
09 Oct 2018 Melbourne, 9 October, 2018 – CSL, the parent company of CSL Behring, today announced an AUD$50,000 donation in support of Indonesian earthquake and tsunami relief efforts. The...
-
Sep 20, 2018
Barbara Angehrn joins Vifor Pharma as Chief Business Officer Patrick Treanor takes over from Scott Garland as President of Relypsa Vifor Pharma announced today changes to its management. Barbara...
-
Sep 18, 2018
Vifor Pharma Group increases equity stake in ChemoCentryx from 6.6% to 21.2%. Vifor Pharma Group acquires an additional 7,343,492 common shares of ChemoCentryx, Inc. (NASDAQ: CCXI) from...
-
Sep 18, 2018Thomson Reuters Includes the Global Biotechnology Leader in its 2018 Top 100 Global Diversity and Inclusion Index
18 Sep 2018 KING OF PRUSSIA, Pa. – September 18, 2018 – Thomson Reuters has ranked global biotechnology leader CSL Limited one of the top 100 companies in its 2018 global Diversity and...
-
Sep 13, 2018• Hosts Patient-Focused Symposium on Alpha 1 Management • Raises Money to Support Disease Awareness
13 Sep 2018 PARIS, France – 13 September 2018 – Global biotherapeutics leader CSL Behring will host a symposium about Alpha 1 Antitrypsin Deficiency (AATD) on Monday, 17 September, during the 28th
-
Aug 28, 2018
Vifor Pharma today announced the launch of an inaugural Swiss Franc straight bond in the amount of CHF 465 million in the Swiss domestic market. The bond carries a 0.75% fixed coupon with a tenor...
-
Aug 23, 2018- The only treatment for hemophilia B FDA approved for up to 14-day dosing is now available in larger, 3500 IU vial size - IDELVION is now offered in 5 convenient vial sizes to fit any dosing regimen: 250, 500, 1000, 2000 and 3500 IU - New vial option delivers on CSL Behring’s promise to enhance current treatments and provide more alternatives to patients
23 Aug 2018 KING OF PRUSSIA, Pa. – 23 August 2018 – Global biotherapeutics leader CSL Behring today announced that IDELVION® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein...
-
Aug 8, 2018
Strong financial performance in H1 2018 Three medium-term strategic growth drivers fully on track #Strategic in-licensing deal concluded with Cara Therapeutics Inc Net sales and EBITDA guidance...
-
Jul 20, 2018• Presentations include new analysis from the PATH trial, the largest clinical trial in CIDP
• CSL Behring is now the only company to offer a portfolio of biologics to address the unique needs of CIDP patients in the US – Hizentra®, the first and only subcutaneous immunoglobulin...
-
Jul 5, 2018- CSL Behring hosts symposium featuring patient perspective on subcutaneous immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) treatment
- CSL Behring offers a portfolio of immunoglobulin therapies to address the unique needs of CIDP patients – Hizentra®, the first and only subcutaneous immunoglobulin option for CIDP patients...
-
Jun 26, 2018
Human Vaccines Project and Seqirus Partner to Advance Universal Flu Vaccine Research New York, NY and Maidenhead, UK — 06/26/2018 The Human Vaccines Project, a nonprofit public-private...
-
Jun 22, 2018Named after coagulation therapy pioneer Prof. Norbert Heimburger, the grant has been awarded this year to researchers from France, Netherlands and the United States.
22 Jun 2018 KING OF PRUSSIA, Pa. – June 22, 2018 – An exciting cross-section of coagulation research is being presented today by the recipients of CSL Behring’s 2018 Prof. Heimburger Award...
-
Jun 15, 2018- CSL Behring offers a portfolio of immunoglobulin therapies to address the unique needs of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) patients - CSL Behring will support an oral presentation and four ePresentations focusing on CIDP treatment during the EAN congress
15 Jun 2018 LISBON, Portugal – 15 June 2018 – Global biotherapeutics leader CSL Behring today announced that it will participate in the 4th Congress of the European Academy of Neurology (EAN)...
-
Jun 1, 2018
$2.5 Million Funding Available to Australian Biomedical Researchers Melbourne, Australia: 01.06.2018 - Australia’s best and brightest biomedical researchers are invited to apply for one of two...
-
May 31, 2018• IDELVION 14-day dosing option for some patients, combined with the larger vial size, will improve convenience with fewer vials and less infusions • New vial option delivers on CSL Behring’s promise to enhance current treatments and provide more alternatives to patients
31 May 2018 KING OF PRUSSIA, Pa. – 31 May 2018 – Global biotherapeutics leader CSL Behring today announced that the US Food and Drug Administration (FDA) has approved a 3500 IU (international...
-
May 23, 2018
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) to develop and commercialise CR845/difelikefalin injection worldwide except in the US, Japan and South Korea for the treatment of chronic kidney...
-
May 18, 2018
CSL Limited today announced a revised profit outlook for fiscal 2018. CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a revised profit outlook for fiscal 2018. The Company now expects net...
-
May 15, 2018
All proposals of the Board of Directors approved by shareholders Election of Jacques Theurillat to the Board of Directors Re-election of standing members of the Board of Directors Dividend of CHF...
-
May 14, 2018HANJ President David Lechner presented the award to Perreault at the association’s 38th Annual Testimonial Dinner Dance
14 May 2018 East Brunswick, N.J. – May 14, 2018 – CEO and Managing Director of CSL Limited Paul Perreault has been named “Humanitarian Man of the Year” by the Hemophilia Association of New...
-
Apr 26, 2018Five patient advocacy organizations are awarded LEAD Grants to support their advocacy initiatives in 2018
26 Apr 2018 KING OF PRUSSIA, Pa. – April 26, 2018 – Patient advocacy groups in Michigan, Washington, Illinois, Missouri and South Carolina are preparing to meet the many challenges standing...
-
Apr 20, 2018- CSL Behring will host an industry therapeutic update highlighting findings from the PATH trial, the largest clinical trial in CIDP, and present key poster presentations featuring advances in the field of NMM
- Exhibition booth (#846) will feature interactive simulation exercises allowing attendees to experience typical CIDP symptoms - CSL Behring is now the only company to offer a portfolio of...
-
Apr 17, 2018
The project is intended to significantly improve access to antivenoms by combining a large antivenom donation, healthcare worker training, with a purpose-built distribution and product management...
-
Apr 12, 2018CSL Behring Marks World Hemophilia Day by Shipping IUs of its Bleeding Disorders Medicines to the World Federation of Hemophilia
12 Apr 2018 MONTREAL and KING OF PRUSSIA, Pa. – April 12, 2018 – The World Federation of Hemophilia (WFH) and global biotherapeutics leader CSL Behring announced today that CSL Behring has...
-
Apr 12, 2018
Seqirus partners with American Nurse Practitioner Foundation, American Pharmacists Association and Physician Assistant Foundation to drive conversation around flu prevention in adults 65 and older...
-
Mar 29, 2018
Jacques Theurillat to be proposed to Annual Shareholder Meeting for appointment to Board Marc de Garidel will not stand for re-election All other members of the Board of Directors will stand for...
-
Mar 23, 2018
23 Mar 2018 KING OF PRUSSIA, Pa. – March 23, 2018 – CSL Behring, a global biotherapeutics leader, today announced the initiation of the AEGIS-II (ApoA-I Event reducinG in Ischemic Syndromes...